CurIOS Therapeutics is a NewCo advancing novel mRNA therapies to target virally-driven cancers. The team is comprised of physician-scientists with deep clinical, immunobiology and translational expertise. We have developed strong preclinical rationale for an mRNA vaccine to Merkel cell carcinoma, a lethal skin cancer with high unmet medical need, including data from animal models and patient samples. Our initial indication is ~18 months from the clinic with a clear path to efficacy trials. We have additionally invented platform approaches to improve antigen prediction and vaccine efficacy that will allow us to lead the development of next generation of mRNA therapeutics.